GM Watch
  • Main Menu
    • Home
    • News
      • Latest News
      • Newsletter subscription
      • Daily Digest
      • News Reviews
      • News Languages
    • Articles
      • GM Myth Makers
      • GM Reports
      • GM Quotes
      • GM Myths
      • Non-GM successes
      • GM Firms
        • Monsanto: a history
        • Monsanto: resources
        • Bayer: a history
        • Bayer: resources
    • Videos
      • Latest Videos
      • Must see videos
      • Cornell videos
      • Agriculture videos
      • Labeling videos
      • Animals videos
      • Corporations videos
      • Corporate takeover videos
      • Contamination videos
      • Latin America videos
      • India videos
      • Asia videos
      • Food safety videos
      • Songs videos
      • Protests videos
      • Biofuel myths videos
      • Index of GM crops and foods
      • Index of speakers
      • Health Effects
    • Contact
    • About
    • Links
    • Donations
    • How donations will help us
News and comment on genetically modified foods and their associated pesticides    
  • News
    • Latest News
    • Newsletter subscription
    • Archive
      • 2019 articles
      • 2018 articles
      • 2017 articles
      • 2016 articles
      • 2015 articles
      • 2014 articles
      • 2013 articles
      • 2012 articles
      • 2011 articles
      • 2010 articles
      • 2009 articles
      • 2008 articles
      • 2007 articles
      • 2006 articles
      • 2005 articles
      • 2004 articles
      • 2003 articles
      • 2002 articles
      • 2001 articles
      • 2000 articles
    • Daily Digest
    • News Reviews
    • News Languages
      • Notícias em Português
      • Nieuws in het Nederlands
      • Nachrichten in Deutsch
  • Articles
    • GM Myth Makers
    • GM Reports
    • How donations will help us
    • GM Quotes
    • GM Myths
    • Non-GM successes
    • GM Firms
      • Monsanto: a history
      • Monsanto: resources
      • Bayer: a history
      • Bayer: resources
  • Videos
    • Index of speakers
    • Glyphosate Videos
    • Latest Videos
    • Must see videos
    • Health Effects
    • Cornell videos
    • Agriculture videos
    • Labeling videos
    • Animals videos
    • Corporations videos
    • Corporate takeover videos
    • Contamination videos
    • Latin America videos
    • India videos
    • Asia videos
    • Food safety videos
    • Songs videos
    • Protests videos
    • Biofuel myths videos
    • Index of GM crops and foods
  • Contact
  • About
  • Links
  • Donations

LATEST NEWS

  • Buy organic food to help curb global insect collapse, say scientists

  • New study questions practice of desiccation with glyphosate herbicide

  • New meta-study reinforces evidence that glyphosate herbicide is probable human carcinogen

  • Monsanto Roundup attacks healthy gut bacteria, lawsuit says

  • West Australian GM compensation report is toothless

GMO INFO

10 Questions About GM Foods
Do GMOs increase yields and reduce pesticide use, and are they needed to feed the world? Find out in the 16-page document, 10 Questions About GM Foods.

LATEST VIDEOS

  • Summary of GMO studies by 25-year expert researcher
  • Why are we being fed by a poison expert?
  • Glyphosate - Harmless tool or sneaky poison (part 2)

News Menu

  • Latest News
  • News Reviews
  • Archive
  • Languages

Please support GMWatch

Donations

You can donate via Paypal or credit/debit card.

Some of you have opted to give a regular donation. This is greatly appreciated as it helps place us on a more stable financial basis. Thank you for your support!

GM mozzies and salmon didn't work for Intrexon – now it gets into cannabis

Details
Published: 27 September 2018
Twitter

Medical Cannabis

Engineering mosquitoes and salmon didn’t capture investors’ imagination – now Intrexon is looking to join the marijuana frontier

Intrexon, the biotech company that has taken over Oxitec of GM mosquitoes fame, has failed to attract investors with its GM salmon and mosquitoes, so now it's getting into the production of cannabis compounds for medical use employing GM yeast.

Bloomberg's header for the article below – "Intrexon, once a fighter of Zika, pivots to join pot mania" – while mildly amusing, has a moral slant that is superfluous.

Intrexon/Oxitec's attempt to flog GM mosquitoes to governments as a way of combatting the mosquito-borne Zika virus, which was blamed for causing a spate of microcephaly in newborns, hardly qualified as a humanitarian crusade.

The evidence for Zika being the main or sole cause of the microcephaly outbreak was always dodgy, as GMWatch repeatedly pointed out during the height of the mosquito-centred hysteria.

And there is evidence that the GM mozzie approach to wiping out mosquito populations has failed.

Like all such GMO ventures, the GM mozzies programme was driven by money rather than humanitarian concerns.

Conversely, Intrexon's new interest, medical cannabis, can hardly be termed "pot mania". Cannabis contains compounds that are of use in some disease conditions and Intrexon will attempt to use GM yeast to produce them.

Let's hope Intrexon does the required tests to check the purity and safety of its product. In the 1980s people in the US got sick and died after ingesting a supplement, l-tryptophan, made from GM bacteria. The illness probably resulted from contaminants introduced into the product by the engineered bacteria. Now tests are available that can detect such problems. Intrexon must ensure that it uses them.
---

Intrexon, once a fighter of Zika, pivots to join pot mania

By Cristin Flanagan
Bloomberg, 24 September 2018
https://www.bloomberg.com/news/articles/2018-09-24/from-zika-to-pot-intrexon-wants-to-join-marijuana-mania?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo

Engineering mosquitoes and salmon didn’t capture investors’ imagination for Intrexon Corp. So now it’s looking to join the marijuana frontier.

The biotech firm run by Chief Executive Officer and Chairman Randal Kirk surged as much as 38 percent intraday, the biggest jump in more than five years, after saying the company had engineered a yeast strain to extract “low-cost, robust and consistent” cannabinoids via a fermentation process for medical use.

Before today, shares had shed more than 68 percent of their value since Sept. 2015 as Intrexon’s forays into genetic engineering including tweaking salmon -- dubbed Frankenfish by detractors -- and mosquitoes to combat the spread of the Zika virus failed to curry favor with investors.

With short interest more than 47 percent of equity float, Intrexon is the most shorted name on the Bloomberg World Index and has been a frequent target of short sellers in the past. Bank of America Merrill Lynch analyst Derik de Bruin also grew more bearish on the billionaire-run company earlier this summer when he cut his rating to a sell, saying any payoff for Intrexon’s more advanced programs in mosquitoes, fish or genetically modified apples was not likely to be significant before 2020.

The company’s executive director of commercial operations said in a press release strains would be optimized for specific cannabinoids that may be commercialized “in the coming years.” A company spokeswoman did not respond to a call requesting comment.

Menu

Home

News

News Archive

News Reviews

Videos

Articles

GM Myth Makers

GM Reports

GM Myths

GM Quotes

How Donations Will Help Us

Contacts

Contact Us

About

Facebook

Twitter

RSS

Content 1999 - 2019 GMWatch.
Web Development By SCS Web Design